Cytokine‐centered strategies to boost cancer immunotherapy
Open Access
- 7 February 2025
- journal article
- Published by Wiley in Molecular Oncology
- Vol. 19 (3) , 579-583
Abstract
Cytokines have gained attention in oncology in recent years, especially in the context of immunotherapy. Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, there are still some challenges to be faced, such as the lack of predictive biomarkers as well as the emergence of resistance and their severe side effects. In this Viewpoint, we discuss the potential of cytokines, the soluble mediators of cancer‐associated inflammation, in immunotherapy. Indeed, both the activation and inhibition of cytokines have been suggested as potential strategies to overcome immunotherapy resistance. In addition, serum levels of certain cytokines can predict response to immunotherapy, and cytokine inhibition could also contribute to prevent side effects induced by ICIs. Thus, although further research is still required, data support that cytokine‐based therapies could be an attractive therapeutic strategy for cancer patients treated with immunotherapy in the near future.Keywords
This publication has 9 references indexed in Scilit:
- Next-generation combination approaches for immune checkpoint therapyNature Immunology, 2024
- Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patientsBritish Journal of Cancer, 2024
- Dictionary of immune responses to cytokines at single-cell resolutionNature, 2023
- New perspectives in cancer immunotherapy: targeting IL-6 cytokine familyJournal for ImmunoTherapy of Cancer, 2023
- CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyCell Reports Medicine, 2023
- IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancerCancer Cell, 2022
- Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityCancer Cell, 2022
- Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironmentJournal of Clinical Investigation, 2022
- The relationships between systemic cytokine profiles and inflammatory markers in colorectal cancer and the prognostic significance of these parametersBritish Journal of Cancer, 2020